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Therapeutic Failure or Resistance to Aspirin
Gum et al. (1) recently published a highly cited study about the
potential clinical consequences of aspirin resistance as assessed by
aggregometry in patients undergoing elective cardiac catheterization.
In a recent reply to comments raised by Steinhubl et al. (2),
Topol and colleagues (3) acknowledge the real possibility of a type
II error to detect an association between long-term outcomes and
aspirin-resistance status as determined by the Platelet Function
Analyzer (PFA-100). In fact, this is a little surprising, because
previous studies indicated that PFA-100 results are highly predic-
tive of clinical outcome in stroke patients receiving aspirin (4) and
in patients with percutaneous interventions of peripheral arteries
who received clopidogrel (5). It is interesting to note that, based on
the percentages of aspirin-sensitive and aspirin-resistant-patients
presented in Gum et al. (1), Gum et al. (6), and Topol et al. (3),
the total number of patients experiencing adverse events is 35 and
43 for aggregometry and PFA-100, respectively. This inconsis-
tency needs further clarification.
What should make the reader more concerned is the high
likelihood for an alpha error regarding the main outcome of Gum
et al. (1) concerning aggregometry: the total number of aspirin-
resistant subjects is limited (n  17 of 326), of whom only four
(24%) experienced an adverse outcome, as compared to 10% of
aspirin-responsive patients. Therefore, statistical significance (p 
0.03) relies on only four events in aspirin-resistant patients, and
even one event less in this group would be likely to yield an
insignificant p value. Considering that the investigators used two
methods to assess aspirin resistance (6), the PFA-100 and the
aggregometry, a p value correction, if done for the two end points,
would also result in an insignificant p value. Thus, statistical
significance is not very robust.
The late occurrence of events is conspicuous because it contrasts
with what has been observed for the clinical efficacy of aspirin
versus placebo, where mortality curves cross after 18 to 24 months
(7). This further increases the chances for an alpha error.
Finally, Topol et al. (3) discuss the poor correlation between
aggregometry and PFA-100. This is not surprising when differ-
ences between methods are considered. The PFA-100 fulfills
several of the characteristics of an ideal and rather physiological
platelet-function test (8,9). First, whole blood is used rather than
platelet-rich plasma. Second, it is a high shear system. This is
important, because the cyclo-oxygenase inhibitor aspirin and the
purinergic receptor inhibitor clopidogrel are primarily used for
arterial indications, which are characterized by high shear rates.
In summary, several trials (1,4,5,10) have generated interest in
investigating the clinical consequences of aspirin and clopidogrel
non-responsiveness, which, it is hoped, will result in adequately
powered confirmatory studies with pivotal results.
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REPLY
In response to the letter by Dr. Jilma, I believe we have fully
addressed his concerns in our primary report (1) and the subse-
quent correspondence (2). The conclusion of our study was that
“further investigation to confirm our findings . . . should be per-
formed.” We fully acknowledged the relatively small sample size,
number of events, and potential for alpha error (1). We also duly
noted the poor correlation of the Platelet Function Analyzer
(PFA) results despite Dr. Jilma’s expectations.
Rather than investigator “resistance,” we invite Dr. Jilma to
perform meaningful prospective research to define further the
natural history of anti-platelet drug lack of responsiveness.
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